Viridian Therapeutics (VRDN) News Today $13.23 -0.30 (-2.22%) As of 11:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Artia Global Partners LP Purchases Shares of 100,000 Viridian Therapeutics, Inc. (NASDAQ:VRDN)Artia Global Partners LP acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 100,000 shares of the company's stock, valued at approximately $1,917,000April 29 at 7:00 AM | marketbeat.comAdage Capital Partners GP L.L.C. Grows Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Adage Capital Partners GP L.L.C. increased its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 38.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,670,000 shares of the company's stockApril 28 at 5:37 AM | marketbeat.comRaymond James Financial Inc. Makes New $6.02 Million Investment in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Raymond James Financial Inc. purchased a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 313,787 shares of the company's stock, vaApril 27 at 3:53 AM | marketbeat.comJ. Safra Sarasin Holding AG Takes $699,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)J. Safra Sarasin Holding AG acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 36,453 shares of the company's stock, valued at approximately $699,000.April 26 at 5:43 AM | marketbeat.comViridian Therapeutics' (VRDN) "Buy" Rating Reiterated at HC WainwrightApril 26 at 2:26 AM | americanbankingnews.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsViridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and nine have asApril 25, 2025 | marketbeat.comViridian Therapeutics' (VRDN) Buy Rating Reiterated at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Wednesday.April 25, 2025 | marketbeat.comSilverarc Capital Management LLC Purchases Shares of 100,000 Viridian Therapeutics, Inc. (NASDAQ:VRDN)Silverarc Capital Management LLC bought a new stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 100,000 shares of the company's stock, valued at approximately $1,917,000. Silverarc Capital MaApril 24, 2025 | marketbeat.comDiadema Partners LP Purchases Shares of 49,478 Viridian Therapeutics, Inc. (NASDAQ:VRDN)Diadema Partners LP acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 49,478 shares of the company's stock, valued at approximatelApril 24, 2025 | marketbeat.comEversept Partners LP Buys 88,766 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Eversept Partners LP boosted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 12.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 779,998 shares of thApril 24, 2025 | marketbeat.com22,972 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Purchased by XTX Topco LtdXTX Topco Ltd acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 22,972 shares of the company's stock, valuedApril 24, 2025 | marketbeat.comVivo Capital LLC Sells 695,631 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Vivo Capital LLC cut its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 41.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 982,576 shares of the company's stock after selling 695,631 shares during the period. Viridian TherapeuticsApril 23, 2025 | marketbeat.comRenaissance Technologies LLC Has $7.12 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Renaissance Technologies LLC raised its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 522.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 371,200 shares of the companApril 21, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co.JPMorgan Chase & Co. decreased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 24.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 304,334 shares of the company's stApril 20, 2025 | marketbeat.comGeode Capital Management LLC Has $31.81 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Geode Capital Management LLC increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,658,980 shares of the company's stock after purchasing an additional 165,669 shareApril 19, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Trading Down 5.6% - Time to Sell?Viridian Therapeutics (NASDAQ:VRDN) Stock Price Down 5.6% - Time to Sell?April 17, 2025 | marketbeat.comAffinity Asset Advisors LLC Reduces Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Affinity Asset Advisors LLC lessened its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 69.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 159,614 shares of the company's stock after selling 365,386 shaApril 17, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Shares Up 6.1% - Here's What HappenedViridian Therapeutics (NASDAQ:VRDN) Trading Up 6.1% - What's Next?April 16, 2025 | marketbeat.comRussell Investments Group Ltd. Has $7.28 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Russell Investments Group Ltd. cut its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 14.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 379,596 shares of the company's stock after selling 62,738 shares during thApril 15, 2025 | marketbeat.comExodusPoint Capital Management LP Takes $493,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)ExodusPoint Capital Management LP purchased a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,724 shares of the company's stocApril 15, 2025 | marketbeat.comFmr LLC Acquires 698,434 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Fmr LLC boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 6.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,881,912 shares of the company's stock after puApril 14, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Stock Position Lifted by Vanguard Group Inc.Vanguard Group Inc. boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 4.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,595,049 shares of the company's stock after buying aApril 12, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Stock Price Down 6.7% - Here's WhyViridian Therapeutics (NASDAQ:VRDN) Shares Down 6.7% - Time to Sell?April 11, 2025 | marketbeat.comAmerican Century Companies Inc. Has $2.18 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)American Century Companies Inc. boosted its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 304.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 113,562 shares of the company's stock after buying an additional 8April 10, 2025 | marketbeat.comViridian Therapeutics (NASDAQ:VRDN) Sets New 12-Month Low - Time to Sell?Viridian Therapeutics (NASDAQ:VRDN) Hits New 52-Week Low - Here's WhyApril 9, 2025 | marketbeat.comTrexquant Investment LP Sells 22,576 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Trexquant Investment LP cut its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 15.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 120,065 shares of the company's stock after selling 22,576April 9, 2025 | marketbeat.comViridian Therapeutics appoints Ajer to its board of directorsApril 8, 2025 | markets.businessinsider.comViridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsApril 7, 2025 | finance.yahoo.comAlliancebernstein L.P. Buys 84,255 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Alliancebernstein L.P. lifted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 3.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,286,994 shares of the company's stock after acquiring an additional 84,255April 7, 2025 | marketbeat.comBryce Point Capital LLC Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Bryce Point Capital LLC bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 44,063 shares of the company's stock, valued at approApril 5, 2025 | marketbeat.com25,000 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Bought by Knott David M JrKnott David M Jr bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the company's stock, valued at approximately $47April 2, 2025 | marketbeat.comPictet Asset Management Holding SA Boosts Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Pictet Asset Management Holding SA increased its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 21.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,248,721 shares of the company's stocApril 2, 2025 | marketbeat.comLoomis Sayles & Co. L P Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Loomis Sayles & Co. L P acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,400,381 shares of the company's stock, valued at apMarch 29, 2025 | marketbeat.comBIT Capital GmbH Increases Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)BIT Capital GmbH boosted its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 239.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 285,954 shares of the company's stoMarch 28, 2025 | marketbeat.comCommit To Buy Viridian Therapeutics At $12.50, Earn 13.2% Annualized Using OptionsMarch 22, 2025 | nasdaq.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by Yiheng Capital Management L.P.Yiheng Capital Management L.P. trimmed its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 750,261 shares of the comMarch 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Charles Schwab Investment Management Inc. boosted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 11.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 575,070 shares of the company's stock after buying an additioMarch 22, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned an average rating of "Moderate Buy" from the twelve ratings firms that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and nine have givenMarch 20, 2025 | marketbeat.comViridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Bank of New York Mellon CorpBank of New York Mellon Corp increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 15.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 196,522 shares of the companyMarch 19, 2025 | marketbeat.com410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc.Victory Capital Management Inc. acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 410,440 shares of the company'sMarch 15, 2025 | marketbeat.comViridian Therapeutics appoints new director, sees board resignationMarch 12, 2025 | investing.comCandriam S.C.A. Has $14.02 Million Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)Candriam S.C.A. decreased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 731,221 shares of the company's stock after selling 18,583 sharMarch 7, 2025 | marketbeat.comResearch Analysts Issue Forecasts for VRDN Q1 EarningsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at B. Riley issued their Q1 2025 earnings per share estimates for Viridian Therapeutics in a research note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will earnMarch 6, 2025 | marketbeat.comFisher Asset Management LLC Acquires 23,103 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)Fisher Asset Management LLC lifted its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 518,027 shares of the company's stock after purchasinMarch 5, 2025 | marketbeat.comQ2 Earnings Forecast for VRDN Issued By B. RileyViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities research analysts at B. Riley issued their Q2 2025 EPS estimates for shares of Viridian Therapeutics in a report issued on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($1.14) per sMarch 4, 2025 | marketbeat.comViridian Therapeutics Faces Uncertainty Amid Regulatory Approval ChallengesMarch 4, 2025 | tipranks.comWhat is Leerink Partnrs' Forecast for VRDN FY2029 Earnings?Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Analysts at Leerink Partnrs dropped their FY2029 earnings per share estimates for shares of Viridian Therapeutics in a research note issued to investors on Thursday, February 27th. Leerink Partnrs analyst T. Smith now forecasts that the coMarch 3, 2025 | marketbeat.comQ1 EPS Estimates for Viridian Therapeutics Raised by WedbushViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at Wedbush increased their Q1 2025 earnings per share estimates for shares of Viridian Therapeutics in a research report issued on Thursday, February 27th. Wedbush analyst L. Chico now anticipates that the company willMarch 3, 2025 | marketbeat.comViridian Therapeutics: Positive Data In TED, Strong Cash Position, 1.5-Year WindowMarch 2, 2025 | seekingalpha.comWedbush Reduces Earnings Estimates for Viridian TherapeuticsViridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Equities researchers at Wedbush lowered their FY2027 earnings estimates for Viridian Therapeutics in a report issued on Thursday, February 27th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $3.77March 1, 2025 | marketbeat.com Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address VRDN Media Mentions By Week VRDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRDN News Sentiment▼1.400.85▲Average Medical News Sentiment VRDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRDN Articles This Week▼135▲VRDN Articles Average Week Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies RDNT News Today SHC News Today PRVA News Today BTSG News Today SGRY News Today WGS News Today CON News Today VCYT News Today LFST News Today PGNY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRDN) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRDN Stock Free VRDN Stock Alerts